Iambic announced an oversubscribed financing topping $100 million to advance its AI‑discovered drug pipeline and platform technologies. The round drew strategic and financial investors, including ARK and Regeneron Ventures, and the company signaled plans to advance multiple programs and strike additional collaborations. Reporting and company statements framed the round as evidence of renewed investor confidence in AI‑enabled discovery firms, with Iambic highlighting clinical candidates and near‑term IND strategies. Coverage noted concurrent partnership activity that leverages the company’s NeuralPLexer model for protein structure prediction and small‑molecule design. The funding will accelerate clinical development and support business development as AI‑first biotechs seek to translate computational leads into de‑risked assets and partner deals.